BRD4354 Is a Potent Covalent Inhibitor against the SARS-CoV-2 Main Protease

Authors:
Publisher website
Google Scholar
Abstract
Numerous organic molecules are known to inhibit the main protease (MPro) of SARS-CoV-2, the pathogen of Coronavirus Disease 2019 (COVID-19). Guided by previous research on zinc-ligand inhibitors of MPro and zinc-dependent histone deacetylases (HDACs), we identified BRD4354 as a potent inhibitor of MPro. The in vitro protease activity assays show that BRD4354 displays time-dependent inhibition against MPro with an IC50 (concentration that inhibits activity by 50%) of 0.72 ± 0.04 μM after 60 min of incubation. Inactivation follows a two-step process with an initial rapid binding step with a KI of 1.9 ± 0.5 μM followed by a second slow inactivation step, kinact,max of 0.040 ± 0.002 min-1. Native mass spectrometry studies indicate that a covalent intermediate is formed where the ortho-quinone methide fragment of BRD4354 forms a covalent bond with the catalytic cysteine C145 of MPro. Based on these data, a Michael-addition reaction mechanism between MPro C145 and BRD4354 was proposed. These results suggest that both preclinical testing of BRD4354 and structure-activity relationship studies based on BRD4354 are warranted to develop more effective anti-COVID therapeutics.
Funding Information
  • Welch Foundation (A-1715, A-1987)
  • Division of Intramural Research (R21AI164088)
  • National Institute of Biomedical Imaging and Bioengineering (R21EB032983)
  • Texas A and M University
  • National Institute of General Medical Sciences (R35GM145351, RM1GM149374, R35GM143047)

This publication has 27 references indexed in Scilit: